secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2022-08-05T23:59:59+00:00
Accession:  0001628280-22-021235
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience Q3 FY2022 revenue $56.1M (+60% YoY), raises FY guidance to $203M
--------------------------------------------------------------------------------

- Revenue $56.1M (+60% YoY from $35.0M); orders $59.7M (+53% YoY).
- Net loss $60.5M ($1.08/sh) vs $40.0M ($0.82/sh) in prior year.
- Cash, cash equivalents and investments total $527.6M as of June 30, 2022.
- FY2022 revenue guidance raised to $203M from prior outlook.
- Launched Twist MRD Rapid 500 Panel, human monkeypox controls, and expanded EUA for SARS-CoV-2 NGS assay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000162828022021235/0001628280-22-021235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000162828022021235/twist-20220805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-021235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer